Redefining Prostate Cancer Care: Balancing Cure, Longevity, and Quality of Life

A prostate cancer diagnosis can leave men weighing several consequential decisions, from active surveillance and regular monitoring to surgery and radiation therapy. Each option may offer a different balance of cancer control, potential side effects, and long-term quality of life. Anxiety about disease progression can influence these choices, particularly when men are asked to make decisions while processing unfamiliar medical information.

According to the American Cancer Society's Cancer Facts & Figures 2026, an estimated 333,830 men in the United States will be diagnosed with prostate cancer this year. The report also notes that treatment decisions can involve weighing potential benefits against urinary difficulties, erectile dysfunction, and other complications. Amid this landscape, the challenge for patients and clinicians may be finding a course of care that reflects the cancer's characteristics alongside the individual's health, priorities, and tolerance for uncertainty.

For Dr. Fernando Bianco, founder and scientific lead of Focalyx, a prostate cancer imaging and focal treatment technology company, these decisions raise a broader question about how physicians define successful treatment. Drawing on decades of experience in urology and oncologic care, he has explored how advances in imaging and targeted intervention may help clinicians consider more individualized options.

"A treatment decision should account for the years a man may live after diagnosis, including the urinary, sexual, and personal dimensions of that life," Dr. Bianco says. "Cancer control matters profoundly, and so does the quality of the life a patient hopes to preserve." His perspective reflects a wider clinical discussion about how treatment decisions can incorporate disease risk, longevity, and the everyday consequences of medical intervention.

According to Dr. Bianco, historically, removing the entire prostate through radical prostatectomy, or treating the gland with radiation, became established options partly because cancer can occur in multiple locations within the same organ. "Clinicians have also had to account for uncertainty about the location and extent of individual lesions, including the possibility of disease beyond the most visible tumor," he adds.

Treating the whole gland may therefore be appropriate for certain patients, particularly when disease characteristics warrant comprehensive intervention. Yet the potential effects on urinary continence and sexual function have encouraged further consideration of how the extent of treatment might correspond to the extent and aggressiveness of the cancer.

Evidence from long-term research has added important context to that discussion. The 15-year results of the ProtecT trial, published in The New England Journal of Medicine in 2023, compared active monitoring, prostatectomy, and radiotherapy among men with localized prostate cancer. Prostate cancer mortality remained low and there were no survival differences across the three groups, while modest differences emerged in disease progression and metastasis. However, there were significant detriments in sexual and urinary functions associated with the treatment arms. The findings illustrate why survival, progression, and treatment-related consequences may each deserve consideration when patients evaluate their options. Individual circumstances and cancer characteristics remain essential to interpreting these results.

Dr. Bianco's clinical experience has contributed to his interest in more precise methods of identifying and treating prostate lesions. As imaging and diagnostic techniques have developed, multiparametric magnetic resonance imaging (MRI), targeted biopsies, and MRI-ultrasound fusion technology have offered clinicians additional information about a tumor's location and characteristics. "MRI can help identify suspicious areas, while targeted biopsy allows physicians to collect tissue samples from selected regions," he explains. Fusion systems combine MRI findings with real-time ultrasound images, a GPS like information that aids clinicians guide instruments toward a previously identified target during a procedure.

These tools may support more informed discussions about the extent of treatment appropriate for an individual patient. Their usefulness depends on image quality, biopsy findings, tumor biology, and the possibility of clinically significant disease elsewhere in the prostate. Precision in identifying a lesion can contribute to treatment planning, while continued monitoring remains important when a patient chooses a targeted intervention or active surveillance.

This diagnostic progress has helped bring focal therapy into discussions about options for selected men with localized prostate cancer. Techniques such as cryoablation, which uses freezing temperatures to destroy targeted tissue; irreversible electroporation, which uses electrical pulses to disrupt cells; laser ablation, which reduces heat to destroy targeted tissue; and high-intensity focused ultrasound (HIFU), which uses concentrated sound energy, can target defined areas of the prostate. "Depending on the technique and the patient's circumstances, focal treatment may offer a potential middle option for men who prefer active intervention while seeking to preserve, rather than hinder, their sexual and urinary function," Dr. Bianco explains.

The role of this treatment category is especially relevant to Dr. Bianco's work with Focalyx, which incorporates image-guided methods into the localization and treatment of prostate lesions. Its place in the broader clinical landscape reflects a developing effort to connect diagnostic precision with decisions about the extent of intervention. Focal therapy remains an area of ongoing evolution, and its long-term effectiveness relative to established treatments continues to require careful study.

For Dr. Bianco, the central consideration is how clinicians can match the intensity of treatment to the characteristics of the disease and the person receiving care. "Precision begins with understanding the individual cancer, but it also requires understanding the individual living with it," he says. "The most appropriate decision may be the one that brings cancer risk, personal priorities, and the possible consequences of treatment into the same conversation." These considerations may include tumor grade and volume, age, overall health, life expectancy, and a patient's preferences concerning potential side effects and follow-up.

Overall, the evolving discussion around prostate cancer treatment suggests that individualized decision-making may play an increasingly important role in clinical practice. Imaging and focal technologies offer additional possibilities for selected patients, while active surveillance, surgery, and radiation remain important options according to disease risk and personal circumstances. As Dr. Bianco's work reflects, the broader goal is to evaluate cancer control alongside the life a patient hopes to lead after diagnosis, allowing treatment decisions to account for both clinical needs and quality of life.